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Available online 18 August 2012Vessel size index (Rv, μm) has been proposed as a quantitative magnetic resonance imaging (MRI) derived
imaging biomarker in oncology, for the non-invasive assessment of tumour blood vessel architecture and
vascular targeted therapies. Appropriate pre-clinical evaluation of Rv in animal tumour models will improve
the interpretation and guide the introduction of the biomarker into clinical studies. The objective of this study
was to compare Rv measured in vivo with vessel size measurements from high-resolution X-ray computed
tomography (μCT) of vascular corrosion casts measured post mortem from the same tumours, with and with-
out vascular targeted therapy. MRI measurements were ﬁrst acquired from subcutaneous SW1222 colorectal
xenografts in mice following treatment with 0 (n=6), 30 (n=6) or 200 mg/kg (n=3) of the vascular
disrupting agent ZD6126. The mice were then immediately infused with a low viscosity resin and, following
polymerisation and maceration of surrounding tissues, the resulting tumour vascular casts were dissected
and subsequently imaged using an optimised μCT imaging approach. Vessel diameters were not measurable
by μCT in the 200 mg/kg group as the high dose of ZD6126 precluded delivery of the resin to the tumour vas-
cular bed. The mean Rv for the three treatment groups was 24, 23 and 23.5 μm respectively; the correspond-
ing μCT measurements from corrosion casts from the 0 and 30 mg/kg cohorts were 25 and 28 μm. The strong
association between the in vivo MRI and post mortem μCT values supports the use of Rv as an imaging bio-
marker in clinical trials of investigational vascular targeted therapies.
© 2012 Elsevier Inc. All rights reserved.Introduction
Susceptibility contrast magnetic resonance imaging (MRI) can be
used for the non-invasive determination of vessel size (Rv, μm) and
fractional blood volume (fBV, %) (Tropres et al., 2001). These quanti-
tative imaging biomarkers have been exploited in vivo to evaluate in-
cipient tumour vascular architecture and function (Douma et al.,
2010; Farrar et al., 2010; Kostourou et al., 2003; Lemasson et al., in
press; Remmele et al., 2011; Robinson et al., 2003b, 2008; Wade
and Kozlowski, 2007), and tumour response to anti-vascular thera-
pies (Beaumont et al., 2009; Howe et al., 2008; Lemasson et al.,
2011; Nielsen, 2007; Ungersma et al., 2010; Valable et al., 2008;
Walker-Samuel et al., 2012). For the determination of Rv, the MRI
transverse relaxation rates R2* and R2 are measured before and after
the intravenous injection of an ultrasmall superparamagnetic iron
oxide (USPIO) particle contrast agent, which consists of a highlyr Research, 15 Cotswold Rd,
61 0846.
nson).
rights reserved.paramagnetic iron oxide crystal core surrounded by a stabilising
shell (Jung and Jacobs, 1995). USPIO particle contrast agents remain
intravascular for the duration of the MRI acquisition, and cause R2*
and R2 to become faster in tissue surrounding blood vessels that are
perfused at the time of injection. The ratio of the resulting changes
in the relaxation rates (ΔR2*/ΔR2) can be related to a weighted
mean vessel size, Rv, via a mathematical model of tumour blood ves-
sel geometry (Tropres et al., 2001; Yablonskiy and Haacke, 1994). The
fractional blood volume can also be estimated from the same mathe-
matical model, using the change in R2* after injection of USPIO con-
trast agent.
Ex vivo analysis of tumour vasculature can be attained via vascular
corrosion casting, which involves injecting a vascular network with a
low viscosity monomer resin, which completely perfuses the vascular
tree, including the micro-capillaries (Konerding et al., 1989). Shortly
after injection, the resin polymerises into a solid acrylic and the sur-
rounding tissue is macerated using an alkaline solution. The remaining
detailed replication of the vascular network allows for a submicrometer
resolution of the cast surface when analysed in the scanning electron
microscope, revealing the nature of the blood vessel under investigation
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(Miodonski et al., 1976; Murakami, 1971). Vascular corrosion casts can
be imaged with high spatial resolution micro tomography (μCT), from
which information, including vessel sizes, can be calculated. This
method has previously been applied tomurine tumour xenografts to in-
vestigate tumour vascular structure and the response of tumour vascu-
lature to novel therapeutics (Abbas et al., 1990; El Emir et al., 2007;
Ferretti et al., 2005; Folarin et al., 2010; Malcontenti-Wilson et al.,
2001; O'Connor et al., 2009; Salmon et al., 2006). Vascular corrosion
casts therefore offer an attractivemethod of validation of both Rv and fBV.
The clinical development of novel tumour vascular targeted thera-
peutics requires the development of more speciﬁc non-invasive bio-
markers of disrupted tumour vasculature, as afforded by Rv and fBV.
Such imaging biomarkers require pre-clinical evaluation before being
deployed in clinical trials (Waterton and Pylkkanen, 2012). In this
study, susceptibility contrast MRI derived values of Rv and fBV were
compared with corresponding measurements from μCT images of vas-
cular corrosion casts obtained from the same SW1222 colorectal cancer
xenografts. In addition, to assess the sensitivity of Rv to changes in the
distribution of tumour blood vessel calibre, SW1222 tumours were
treated with the vascular disrupting agent ZD6126 in order to provide
a perturbation of tumour vascular structure. ZD6126 has been shown
to cause massive central necrosis in a range of solid murine xenograft
models 24 h after treatment, caused by acute and catastrophic vascular
collapse (Blakey et al., 2002; Robinson et al., 2003a). Perturbations in
the distribution of blood vessel calibre post treatment with ZD6126
can be measured from μCT images of vascular corrosion casts, thereby




Human SW1222 colorectal tumour cells were cultured in Dulbecco's
Modiﬁed EaglesMedium (DMEM; Invitrogen, Paisley, UK) supplemented
with 10% (v/v) foetal bovine serum, 5 mM L-glutamine, 100 IU/ml
penicillin and 100 μg/ml streptomycin (all Invitrogen). Cells were
maintained at 37 °C in a humidiﬁed 5% CO2 atmosphere.
Tumour propagation
All experiments were performed in compliance with licences is-
sued under the UK Animals (Scientiﬁc Procedures) Act 1986 follow-
ing local ethical review, and with the United Kingdom National
Cancer Research Institute guidelines for the welfare of animals in
cancer research (Workman et al., 2010). Female NCr nude mice,
under isoﬂurane anaesthesia, were injected subcutaneously on the
right ﬂank with 5×106 SW1222 cells. The SW1222 tumours were im-
aged approximately two weeks after inoculation, when they had
reached an average diameter of 1 cm.
Formulation of ZD6126
ZD6126 (prodrug of N-acetylcolchinol, Angiogene, UK) was for-
mulated in 20% of 5% sodium carbonate and 80% phosphate-
buffered saline, yielding a clear solution at pH 7.
Vessel size index (VSI) MRI protocol
Prior to MR imaging, anaesthesia was induced by an intraperitoneal
injection of 10 ml/kg of fentanyl citrate (0.315 mg/ml) plus ﬂuanisone
(10 mg/ml) (Hypnorm, Janssen Pharmaceutical, High Wycombe, UK),
midazolam (5 mg/ml) (Hypnovel, Roche, Burgess Hill, UK), and
water (1:1:2). A lateral tail vein was cannulated with a 27G butterﬂy
catheter (Venisystems; Hospira, Royal Leamington Spa, UK) for remoteadministration of USPIO particles (ferumoxtran-10, Sinerem®, Guerbet,
Roissy, France). During imaging all mice were restrained using dental
paste in order to limit motion artefacts (Landuyt et al., 2002). A warm
air blowerwas used tomaintain the animal's core temperature at 37 °C.
Mice were imaged 24 h after an i.p. injection of 30 (n=6) or
200 mg/kg (n=3) ZD6126, or vehicle alone (n=6). All images were
acquired on a 7 T horizontal bore microimaging system (Bruker,
Ettlingen, Germany) using a 3 cm birdcage coil. Field homogeneity
was optimised over the entire tumour volume using FASTMAP. Follow-
ing tumour localisation using a set of T2-weighted TurboRARE images,
diffusion weighted spin-echo (DWSE, 6 b-values ranging from 6 to
504 s/mm2 in the read direction, gradient strength=0 to 0.1 T/m, gra-
dient duration=5 ms, gradient spacing=25 ms, TR=1000 ms, TE=
36 ms), multiple gradient echo (MGE, TR=300 ms, 8 echo times rang-
ing from TE=6.1 to 28.2 ms, ﬂip angle=45°, 16 averages) and two sep-
arate sets of spin echo (SE, TR=3000 ms, 2 echo times of either 8 or
80 ms, ﬂip angle=90°, 2 averages) images were acquired for determi-
nation of the apparent diffusion coefﬁcient (ADC), R2* andR2 respective-
ly (Walker-Samuel et al., 2012). All images were acquired from three
contiguous 1 mm slices through the tumour centre, with identical
geometry (for all image acquisitions ﬁeld of view=3×3cm, matrix
size=64×64). A second set of identical MGE and SE images were ac-
quired 2 min after the i.v. injection of 200 μmol/kg ferumoxtran-10, to
allow for a steady state distribution of contrast agent throughout the
vascular network.
Calculation of Rv (μm) and fractional blood volume (fBV, %)
Regions of interest (ROIs) corresponding to tumour regions, but
excluding the skin, were drawn on DWSE, MGE and SE images. Esti-
mates of ADC, R2* and R2 were evaluated using a Bayesian hierarchical
model which calculates the uncertainty associated with each esti-
mate, and allows non signiﬁcantly enhancing voxels, post USPIO par-
ticle injection, to be excluded (Walker-Samuel et al., 2010). MRI
relaxation rates R2 and R2* were calculated from SE and MGE images
respectively, as were changes in these MRI relaxation rates, ΔR2* and
ΔR2, post injection of USPIO particles (Walker-Samuel et al., 2012).
Tumour fBV and Rv were then calculated from ΔR2, ΔR2*, and ADC,
using the following relationships, originally deﬁned in the methods












Microvascular corrosion casting protocol
Immediately after the MRI acquisition, each animal was killed by
asphyxiation. Following a midline laparotomy, the ascending carotid
and the femoral arteries were ligated using household thread. This
step was taken to isolate, and ensure good injection pressure, to the
skin. The chest was then opened along the sternum to expose the
heart, the ascending aorta isolated, and a ligature passed underneath
it. A small puncture was made in the bottom of the heart using micro
scissors, and a blunted 25G butterﬂy cannula was inserted through
the heart and into the ascending aorta, where it was secured using
the previously positioned ligature that was passed underneath the
aorta. Physiological saline (10 ml) was injected through the cannula
at 60 ml/h using a syringe driver (Harvard Apparatus, Tonbridge,
UK), and a small incision was made in the right ventricle to form an
open system, ensuring that blood was ﬂushed from the entire vascular
network. Once the saline injection was complete, after approximately
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with a catalyst to begin the polymerising process (0.3 g catalyst per
10 ml resin), and injected via the same cannula at 60 ml/h until the vas-
cular bedwas completely perfused with resin. Mercox is a low viscosity
resin which begins to polymerise to form a solid acrylic upon contact
with the catalyst. Using 0.3 g of catalyst per 10 ml resin gives a pot
life of 10 min, which was sufﬁcient to allow infusion of approximately
9 ml of resin before complete polymerisation, and a sufﬁcient volume
to completely perfuse the abdominal viscera and the subcutaneous tu-
mours inmice. Following perfusion, the resin was allowed to complete-
ly polymerise, which took approximately 2 h, after which the entire
mouse was placed in 7.5% potassium hydroxide solution for 48 h to
macerate. Once maceration was complete, the tumours were dissected,
cleaned in distilled water, frozen, and ﬁnally freeze dried. The freeze
drying step prevented the forces that would be exerted on the cast dur-
ing air drying from damaging delicate microvessel structures. Once the
casts were fully prepared, they were mounted on a scanning podium,
and μCT images were acquired using a Nikon X-tek XTH225 CT system
(Nikon Metrology, X-tek, Tring, UK).
Calculation of vessel diameter from μCT data
A histogram of vessel diameters was derived from each μCT
reconstructed data set using Avizo 6.3 image processing software
(VSG Inc., Burlington, MA). The cast was segmented from background
using the ‘magic wand’ region growing tool. The AutoSkeleton mod-
ule was then applied to derive a 3-D skeletonised image from which
the distribution, and mean value, of the vessel diameters was calcu-
lated using the RadiusHist module.
Prior to the analysis of all casts, the effect of μCT spatial resolution
on the calculation of vessel diameters was ﬁrst investigated by scan-
ning one vascular cast using two tomography systems to give a
range of spatial resolutions. The higher resolutions were provided
by an Xradia microXCT-400 system (Xradia Inc, Pleasanton, CA),
which features a lens-based high resolution detector. Scans were car-
ried out using the 10× and 4× objectives, giving projection image
pixel sizes of 1.2 and 2.4 μm respectively. In both cases, a source volt-
age of 40 kV was used, with 1801 projections being taken over 184°.
In-line phase contrast was used together with phase retrieval using
the TIE-HOM algorithm to improve SNR of the projection images
(Bradley et al., 2010; Keyriläinen et al., 2010). A lower resolution ab-
sorption contrast scan was taken using the Nikon X-tek XTH225 sys-
tem, with a source voltage of 47 kV and 2884 projection images being
taken over 360°. 3-D volumetric data was derived from the raw pro-
jection images via the FDK reconstruction algorithm (Kak and
Slaney, 1988). The range of resolutions was extended by down-
sampling the 3-D volumetric data, to give voxel sizes of 1.2, 2.4 and
4.7 μm for the Xradia data, and 10.2 and 17.9 μm for the X-tek data.
The reconstructed data were then cropped to give the same cast
volume in all cases, but at a range of resolutions. Gold beads were
placed on the cast to enable the same region to be identiﬁed in all
cases. For the highest resolution data, the large number of voxels
(2048×2048×2048) made direct application of the skeletonisation
method computationally prohibitive. Therefore the data was split
into 400 slice thick sections, and the skeletonisation procedure was
applied on each separately. The ﬁnal mean vessel diameter was
then calculated as an average over all the sections. Subsequently, all
casts were scanned on the Nikon X-tek system, using a 16.4 μm
voxel size, corresponding to a minimum detectable radius compara-
ble to that of the MRI measurements at ~8 μm.
The VSI MRI approach provides estimates of median tumour ves-
sel diameter using data from three contiguous image slices approxi-
mately through the centre of a tumour, whereas the μCT method
analyses (in terms of average or median values etc.) vessel diameters
from the entire tumour volume. To investigate the effect of this dif-
ference in sampled tumour volume on the calculated mean vesseldiameter, the μCT vessel diameter measurement method was also
applied to three contiguous 1 mm slices through the centre of the
3D reconstruction of two vehicle vascular casts.
Statistics
All data are reported as mean±1 s.e.m., calculated from the stan-
dard deviation of each treatment group, unless otherwise stated.
Signiﬁcance testing employed the non-parametric Mann–Whitney U
test, with a 5% level of signiﬁcance.
Results
Representative MRI derived Rv and fBV maps, and μCT images of
microvascular corrosion casts from the same SW1222 xenografts, re-
vealing the relationship of the spatial distribution of blood volume
and vessel size, and their response to ZD6126, are shown in Fig. 1.
The number of signiﬁcantly enhancing voxels in the MRI image
maps was seen to decrease between vehicle and treated groups, and
this effect was more exaggerated in tumours from mice treated
with 200 mg/kg than 30 mg/kg ZD6126. Quantitation of the MRI
data revealed that, compared to the vehicle group, fBV was lower in
tumours treated with either 30 or 200 mg/kg ZD6126, and was highly
signiﬁcant (pb0.01) in the cohort treated with 200 mg/kg (Table 1).
The ZD6126-induced decrease in fBV corresponded with areas of
low, or zero vascular density on the μCT images of vascular corrosion
casts obtained from the same tumours.
No signiﬁcant difference in Rv was found across the treatment
groups (Table 1). Plotting the distribution of Rv values for each treat-
ment group in a normalised frequency histogram illustrates that
only subtle changes in the distribution of Rv values were measured
with increasing dose of ZD6126 (Fig. 2). The distribution of Rv values
did not differ between the vehicle, 30, or 200 mg/kg treated
tumours, although a slight decrease in the frequency of Rv values be-
tween 12 and 40 μm is apparent in the cohort treated with 200 mg/
kg, compared to the 30 mg/kg and vehicle groups. Table 1 shows the
25th and 75th percentiles of Rv, calculated from each voxel from
every tumour included in the study. The 25th percentile of Rv was
signiﬁcantly lower (pb0.05) in tumours from mice treated with
ZD6126. There was no difference in the 75th percentiles between
any of the groups.
The variation of calculated mean vessel diameter determined from
the μCT data, with reconstructed voxel size, is shown in Fig. 3a,
highlighting that as the voxel size was increased, the mean vessel di-
ameter increased. As shown in Fig. 3b, at the highest resolution, the
histogram of vessel sizes has only one peak, indicating that there is
sufﬁcient resolution to accurately determine the median radius to
be 6.3 μm. With decreasing the resolution, a second maximum
appears in the histogram at the lowest voxel size. At a voxel size of
16.8 μm, which provides a limit on the smallest detectable vessel sim-
ilar to that of the MRI technique, the majority of the detected vessels
have a diameter at this limit.
Median values of vessel diameter calculated using just three con-
tiguous 1 mm slices through the centre of the 3D reconstructed μCT
images of SW1222 vascular casts are shown in Table 2. The corre-
sponding mean vessel diameters, calculated from the entire 3D
reconstructed datasets, are shown for comparison. There was no sig-
niﬁcant difference between median vessel diameters calculated from
just the three 1 mm slices, or from the full data.
The vascular casting procedure failed in all of the mice treated
with 200 mg/kg ZD6126, a consequence of the extreme reduction in
fBV in the SW1222 tumours 24 h after treatment, precluding ade-
quate resin delivery. Corresponding vessel diameter measurements
made from μCT images of vascular corrosion casts of the same
SW1222 tumours that underwent the VSI imaging protocol are
shown in Table 3. There was no signiﬁcant difference in mean vessel
Fig. 1. a) Representative parametric Rv (μm) and fBV (%) MRI maps acquired from SW1222 colorectal xenografts 24 h after treatment with either vehicle, 30 or 200 mg/kg of the
vascular disrupting agent ZD6126. b) μCT images of the corresponding vascular corrosion casts obtained from the same tumours from mice treated with vehicle or 30 mg/kg
ZD6126. The images show the skeletonization of the CT data where the colour of the vessels is varied linearly with diameter, from blue≤16.8 µm, to red≥270 µm. The vessel thick-
nesses/diameters are rendered with reduced scale/size to aid visualization. No μCT data is presented from tumours treated with 200 mg/kg ZD6126, as treatment decreased the fBV
so dramatically as to inhibit adequate resin perfusion.
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in agreement with the Rv data. Comparison of the mean μCT and me-
dian MRI derived vessel diameters revealed a strong association be-
tween the two measurement methods. VSI estimated that median
Rv diameters were 24±2 and 23±3 μm, and the corresponding μCT
measurements from corrosion casts were 25±2 and 28±4 μm, for
the vehicle and treated tumours, respectively.
Discussion
Traditional response evaluation criteria in solid tumours (RECIST)
use a reduction in tumour volume as a measure of response to therapy.
However, vascular targeted therapies are not predicted to be directlyTable 1
Summary of the quantitative MRI data. MRI derived fractional blood volume (fBV, %)
and weighted vessel diameter (Rv, μm)measurements determined from SW1222 xeno-
grafts 24 h after treatment with either vehicle, 30 or 200 mg/kg ZD6126. Data are me-
dian, and mean±1 s.e.m. of the median values obtained from each imaged slice for
each tumour, #p=0.09, **pb0.01, one-tailed Mann–Whitney test. Also shown are the
mean 25th and 75th percentiles of Rv. Data are mean±1 s.e.m, *pb0.05, two-tailed
Mann–Whitney test.
Vehicle (n=6) 30 mg/kg (n=6) 200 mg/kg (n=3)
fBV Rv fBV Rv fBV Rv
Median 13.5 24.4 12.3 21.2 1.8 20.3
Mean 13.2±1 24.3±2 11±1# 23.3±3 2±0.5** 23.5±6
25th percentile 12±2 7±1* 6±2*
75th percentile 58±10 80±8 59±26cytotoxic and cause signiﬁcant tumour regressions, and hence changes
in tumour volume are an inappropriate indicator of treatment efﬁcacy.
For this reason, non-invasive functional imaging biomarkers are contin-
ually being identiﬁed and validated for the evaluation of novel thera-
peutics (Waterton and Pylkkanen, 2012).
Susceptibility contrast MRI with USPIO particles provides quantita-
tive biomarkers of weighted mean vessel diameter (Rv, μm), and frac-
tional blood volume (fBV, %) (Tropres et al., 2001; Yablonskiy andFig. 2. Normalised frequency histogram of Rv (μm) values, determined from SW1222
tumours 24 h after treatment with either vehicle (n=6), 30 mg/kg (n=6), or
200 mg/kg (n=3) ZD6126.
Fig. 3. (a) Variation of mean vessel diameter with voxel size of the tomography data.
The error bars show the standard deviations calculated from the vessel diameter distri-
butions, and (b) comparison of the distribution of vessel diameters for a voxel size of
1.2 and 2.4 μm.
Table 3
Mean vessel diameter measured from μCT images of microvascular corrosion casts of
SW1222 xenografts 24 h after treatment with either vehicle (n=4) or 30 mg/kg
ZD6126 (n=5). Data are mean±1 s.e.m. of the values obtained from each imaged cast.
Vehicle (n=4) 30 mg/kg (n=5)
Mean vessel diameter (μm) 24.5±2 28.4±4
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sponse to anti-vascular treatment, and the imaging data shown to cor-
relate with appropriate histological measures, such as ﬂuorescence
microscopy of the uptake of the perfusion marker Hoechst 33342
(Robinson et al., 2007). Validation of Rv has been typically pursued
using immunohistochemical detection of pan-endothelial markers
such as CD31 or collagen type IV, morphometric analysis of Hoechst
33342 uptake in individual vessels, and two photon laser scanning mi-
croscopy methods, to measure vessel diameter from tissue samplesTable 2
Comparison ofmedian vessel diameters (μm) calculated from just three contiguous 1 mm
slices through the centre of the full μCT rendering of SW1222 vascular corrosion casts
obtained from two vehicle treated mice, and the mean vessel diameters calculated from
the full 3D reconstructed μCT images. Values are median or mean±standard deviation.
Slice 1 Slice 2 Slice 3 Median Mean
(whole tumour)
Cast 1 22±16 23.6±20 21.8±14 22.4±1 24±26
Cast 2 21.6±30 18.2±8 17.4±16 19±1 18.4±14(Douma et al., 2010; Howe et al., 2008; Lemasson et al., in press;
Remmele et al., 2011; Robinson et al., 2008; Tropres et al., 2004;
Valable et al., 2008; Walker-Samuel et al., 2012). A common inference
from these studies was that susceptibility MRI tended to overestimate
median vessel diameter, but that Rv shows signiﬁcant correlations
with histological vessel size measurements for themeasurement of dif-
ferences in vessel diameter distributions. The variance may be a conse-
quence of structural deformations that occur with histological tissue
preparation.
In this study, Rv was quantiﬁed from SW1222 colorectal xenografts,
and compared with vessel diameters measured from μCT images of mi-
crovascular corrosion casts derived from the same tumours. The Rv for
control SW1222 tumours was ~24 μm,which is similar to that reported
in a wide range of subcutaneously propagated xenografts (Douma et al.,
2010), and smaller than that determined in orthotopically propagated
xenografts (Wade and Kozlowski, 2007; Walker-Samuel et al., 2012).
Collectively, these data highlight the importance of site of tumour
propagation on the subsequent developing vascular morphology.
Importantly, an excellent association between Rv and the tumour vessel
diameter derived from μCT of the vascular corrosion casts was found,
providing strong qualiﬁcation of the MR imaging biomarker (Waterton
and Pylkkanen, 2012).
The vascular disrupting agent ZD6126 was used to perturb the tu-
mour vasculature. Treatment with ZD6126 elicited a dose-dependent
reduction in fBV of SW1222 tumours compared to vehicle control,
and which was primarily associated with the tumour core. Similar de-
creases in fBV following treatment with vascular disrupting agents
have been reported in other tumour models (Bradley et al., 2007;
Robinson et al., 2007; Vogel-Claussen et al., 2007; Walker-Samuel
et al., 2012). Interestingly, there was no associated difference in Rv
between vehicle and ZD6126 treated tumours, and which was con-
ﬁrmed by μCT imaging of the corrosion casts. Together this suggests
that treatment with ZD6126 signiﬁcantly reduced functional tumour
vasculature, but had no effect on the distribution of vessel calibre. It
could thus be hypothesised that ZD6126 can indiscriminately target
both immature small blood vessels, and more mature larger vessels.
Histogram analysis of the distribution of Rv can provide a deeper
interrogation of susceptibility contrast MRI data (Howe et al., 2008;
Just, 2011; Walker-Samuel et al., 2012). The histograms in Fig. 3 illus-
trate that, although there was no difference in the median value of Rv
in any of the tumour cohorts, values from all groups exhibited a dif-
ferent shaped distribution in the range of 12 to 44 μm. This difference
was most pronounced in the ZD6126 treated cohorts, suggesting that
treatment inﬂuenced the distribution of vessel diameters in this
range. Accordingly, the 25th percentiles of Rv were signiﬁcantly
lower in tumours treated with ZD6126 compared to vehicle controls.
Previous studies have reported similar decreases in the 25th percen-
tile of Rv in response to other vascular disrupting agents (Howe et al.,
2008; Walker-Samuel et al., 2012). Collectively, these data suggest
that the 25th percentile may be a more sensitive measure of changes
in vessel calibre than the median.
This study also describes optimisation of approaches for μCT imag-
ing of microvascular corrosion casts. An important factor was found
to be the μCT resolution. As the μCT imaging voxel size used for
image acquisition was increased, there was an associated increase in
vessel diameter (Fig. 3). Data acquired using a 1.2 μm voxel showed
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size was doubled to 2.4 μm. This arises from partial volume effects,
where the grey level of a voxel is increased above the background
level by the presence of a vessel contained within it, even though
the vessel itself cannot be fully resolved. As the voxel size increases
from 1.2 μm and approaches the radii of the smallest capillaries,
around 6 μm, there is a decrease in mean vessel size, as the secondary
maximum is at a lower radius than the ‘true’ maximum. Once the
voxel size becomes greater than the smallest true vessel diameter
the calculated mean diameter increases with voxel size. The results
therefore suggest that a voxel size of less than 2 μm is required to ac-
curately determine the mean and vessel diameter. However, at this
resolution, the reconstructed volume is only ~30 mm3, and therefore
over 20 scans would typically be required from each cast to deter-
mine the vessel calibre over the entire cast. Alternatively, the cast
could be sampled with a smaller number of scans; however care
would have to be taken to ensure that the samples were representa-
tive given the heterogeneous spatial distribution of vessels. At lower
μCT resolutions, despite overestimation, the median and diameters
would still be representative of the vessels that can be detected at
that resolution and hence indicative of the relative proportions of
small (at or around the spatial resolution limit) and larger vessels
within the cast. Thus, the results from different vascular casts can
still be compared, provided that the same resolution is used in all
cases. Therefore, a voxel size of 16.4 μm, corresponding to a minimum
detectable radius comparable to that of the MRI measurements at
~8 μm was used, enabling the whole cast to be analysed from one
scan (Tropres et al., 2001).
There was no signiﬁcant difference between median vessel diam-
eters calculated using just three contiguous 1 mm slices through full
3D rendered μCT images of the vascular corrosion casts, and mean
vessel sizes measured from the whole tumour μCT images. There
appeared thus to be no added value in attempting to spatially
match the μCT measurements of vessel diameter from vascular corro-
sion casts with the slice positions of the MRI images. Additionally,
analysing the distribution of vessel sizes in three 1 mm slices through
a large 3D μCT dataset is less time consuming than analysing a whole
3D image.
To conclude, despite a signiﬁcant decrease in fractional blood vol-
ume, no decrease in mean MRI-derived vessel calibre (Rv) was deter-
mined in subcutaneously propagated SW1222 colorectal xenografts
24 h after treatment with ZD6126. A signiﬁcant decrease in the 25th
percentile of Rv with treatment was determined, suggesting predom-
inant anti-vascular effects on relatively smaller calibre vessels. A
strong association was found between Rv and mean vessel diameters
measured from μCT images of microvascular vascular corrosion casts
generated from the same SW1222 tumours immediately following
the MRI acquisition, providing a powerful technique for the validation
of changes in tumour Rv following anti-vascular treatment.Acknowledgments
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